Allakos Inc. (NASDAQ:ALLK) CFO Harlan Baird Radford Sells 87,064 Shares

Allakos Inc. (NASDAQ:ALLK) CFO Harlan Baird Radford sold 87,064 shares of Allakos stock in a transaction on Friday, June 28th. The stock was sold at an average price of $1.01, for a total value of $87,934.64. Following the sale, the chief financial officer now directly owns 204,390 shares of the company’s stock, valued at $206,433.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Allakos Stock Down 4.5 %

NASDAQ ALLK traded down $0.04 during trading on Tuesday, reaching $0.84. 756,866 shares of the stock traded hands, compared to its average volume of 1,054,483. The stock’s 50-day moving average price is $1.20 and its 200 day moving average price is $1.49. Allakos Inc. has a fifty-two week low of $0.83 and a fifty-two week high of $5.64.

Allakos (NASDAQ:ALLK) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.09). Analysts expect that Allakos Inc. will post -1.24 EPS for the current year.

Wall Street Analysts Forecast Growth

ALLK has been the topic of a number of analyst reports. Cantor Fitzgerald reiterated a “neutral” rating on shares of Allakos in a research report on Thursday, June 20th. JMP Securities restated a “market outperform” rating and set a $3.00 price objective on shares of Allakos in a report on Wednesday, June 26th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $1.83.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Aristides Capital LLC bought a new stake in shares of Allakos in the fourth quarter worth $153,000. BNP Paribas Financial Markets lifted its position in shares of Allakos by 1,041.1% in the first quarter. BNP Paribas Financial Markets now owns 205,663 shares of the company’s stock worth $259,000 after purchasing an additional 187,640 shares in the last quarter. Pennant Investors LP bought a new stake in shares of Allakos in the fourth quarter worth $508,000. GSA Capital Partners LLP bought a new stake in shares of Allakos in the first quarter worth $929,000. Finally, Ikarian Capital LLC lifted its position in shares of Allakos by 293.4% in the first quarter. Ikarian Capital LLC now owns 932,675 shares of the company’s stock worth $1,175,000 after purchasing an additional 695,619 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

About Allakos

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.